Today, the World Health Organization (WHO) published its first-ever position paper on immunization products to protect ...

Respiratory syncytial virus (RSV) is the number one cause of hospitalization in infants, accounting for about 25% of all ...

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

Patients with respiratory syncytial virus (RSV) hospitalization have increased odds of any acute cardiovascular event ...

Universal immunisation with nirsevimab significantly reduces hospitalizations and paediatric intensive care admissions for ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

The new three-illness dashboard includes a history of outbreaks for any or all of the three respiratory illnesses. It ...

Discover how monoclonal antibody immunisation in Spain was vastly more effective than maternal vaccination in the UK.